Search Results - "Dimicoli‐Salazar, Sophie"

The presence of a chromosomal abnormality in cytopenia without dysplasia identifies a category of high‐risk clonal cytopenia of unknown significance by Brett, Victor‐Emmanuel, Lechevalier, Nicolas, Trimoreau, Franck, Dussiau, Charles, Dimicoli‐Salazar, Sophie, Coster, Lucie, Luquet, Isabelle, Nadal, Nathalie, Ribourtout, Bénédicte, Chapiro, Elise, Lefebvre, Christine, Tondeur, Sylvie, Balducci, Estelle, Nguyen‐Khac, Florence, Borie, Claire, Radford‐Weiss, Isabelle, Barin, Carole, Eclache, Virginie, Mansier, Olivier, Bidet, Audrey

“…Myelodysplastic syndromes (MDS) are hematological malignancies classically defined by the presence of cytopenia(s) and dysmorphic myeloid cells. It is now…”
Get full text

A randomised phase II study of azacitidine (AZA) alone or with Lenalidomide (LEN), Valproic acid (VPA) or Idarubicin (IDA) in higher‐Risk MDS or low blast AML: GFM's “pick a winner” trial, with the impact of somatic mutations by Adès, Lionel, Duployez, Nicolas, Guerci‐Bresler, Agnes, Laribi, Kamel, Peterlin, Pierre, Vey, Norbert, Thepot, Sylvain, Wickenhauser, Stefan, Zerazhi, Hacene, Stamatoullas, Aspassia, Wattel, Eric, Recher, Christian, Toma, Andrea, Dimicoli‐Salazar, Sophie, Braun, Thorsten, Beyne‐Rauzy, Odile, Marolleau, Jean‐Pierre, Cheze, Stéphane, Park, Sophie, Cluzeau, Thomas, Nimubona, Stanislas, Bordessoule, Dominique, Benramdane, Riad, Quesnel, Bruno, Amé, Shanti, Botton, Stéphane, Chermat, Fathia, Preudhomme, Claude, Chevret, Sylvie, Fenaux, Pierre

“…In order to improve the outcome observed with azacitidine (AZA) in higher‐risk Myelodysplastic syndrome (MDS), its combination with other drugs in MDS must be…”
Get full text

Red blood cell transfusion burden in myelodysplastic syndromes (MDS) with ring Sideroblasts (RS): A retrospective multicenter study by the Groupe Francophone des Myélodysplasies (GFM) by Jouzier, Claire, Cherait, Amina, Cony‐Makhoul, Pascale, Hamel, Jean‐François, Veloso, Melanie, Thepot, Sylvain, Cluzeau, Thomas, Stamatoullas, Aspasia, Garnier, Alice, Guerci‐Bresler, Agnès, Dimicoli‐Salazar, Sophie, Pica, Gian Matteo, Cheze, Stéphane, Santana, Clémence, Chermat, Fatiha, Fenaux, Pierre, Park, Sophie

“…Background MDS‐RS patients are characterized by chronic anemia and a low risk of Acute Myeloid Leukemia (AML) progression and they generally become Red Blood…”
Get full text

Efficacy and safety of mammalian target of rapamycin inhibitors in systemic mastocytosis: A nationwide French pilot study by Moraly, Josquin, Rossignol, Julien, Rouzaud, Claire, Gabas, Thomas, Bouktit, Hassiba, Lhermitte, Ludovic, Canioni, Danielle, Fraitag, Sylvie, Bruneau, Julie, Barete, Stéphane, Suarez, Felipe, Ballul, Thomas, Meni, Cécile, Polivka, Laura, Terriou, Louis, Launay, David, Bouillet, Laurence, Gaudy‐Marqueste, Caroline, Gousseff, Marie, Le Mouel, Edwige, Neel, Antoine, Ranta, Dana, Jaussaud, Roland, Guilpain, Philippe, Frenzel, Laurent, Agopian, Julie, Dubreuil, Patrice, Greco, Céline, Dimicoli‐Salazar, Sophie, Heiblig, Mael, Gourguechon, Clément, Tournilhac, Olivier, Javier, Rose‐Marie, Castelain, Florence, Cabrera, Quentin, Gourin, Marie Pierre, Wierzbicka‐Hainaut, Ewa, Torregrosa‐Diaz, Jose Miguel, Bulai, Cristina, Lavigne, Christian, Hoarau, Cyrille, Arock, Michel, Damaj, Gandhi, Lortholary, Olivier, Hermine, Olivier

“…Systemic mastocytosis (SM) corresponds to a rare and heterogeneous spectrum of diseases characterized by the accumulation of atypical mast cells (MCs)…”
Get full text

Myelodysplastic syndrome (MDS) with isolated trisomy 8: a type of MDS frequently associated with myeloproliferative features? A report by the Groupe Francophone des Myélodysplasies by Drevon, Louis, Marceau, Alice, Maarek, Odile, Cuccuini, Wendy, Clappier, Emmanuelle, Eclache, Virginie, Cluzeau, Thomas, Richez, Valentine, Berkaoui, Inès, Dimicoli‐Salazar, Sophie, Bidet, Audrey, Vial, Jean‐Philippe, Park, Sophie, Vieira Dos Santos, Christina, Kaphan, Eléonore, Berthon, Céline, Stamatoullas, Aspasia, Delhommeau, François, Abermil, Nassera, Braun, Thorsten, Sapena, Rosa, Lusina, Daniel, Renneville, Aline, Adès, Lionel, Raynaud, Sophie, Fenaux, Pierre

“…Summary Isolated trisomy 8 (+8) is a frequent cytogenetic abnormality in the myelodysplastic syndromes (MDS), but its characteristics are poorly reported. We…”
Get full text

Impact of Mutational Status and Prognostic Factors on Survival in Chronic Myelomonocytic Leukemia With Systemic Inflammation and Autoimmune Disorders by Dussiau, Charles, Dupuy, Henry, Bidet, Audrey, Sauvezie, Mathieu, De‐Grande, Anne‐Charlotte, Boureau, Lisa, Riviere, Etienne, Forcade, Edouard, Bonnet, Fabrice, Dumas, Pierre‐Yves, Duffau, Pierre, Pigneux, Arnaud, Viallard, Jean‐François, Dimicoli‐Salazar, Sophie, Lazaro, Estibaliz

Get full text

Efficient in vitro myogenic reprogramming of human primary mesenchymal stem cells and endothelial cells by Myf5 by Dimicoli-Salazar, Sophie, Bulle, Frederique, Yacia, Azzedine, Massé, Jean-Marc, Fichelson, Serge, Vigon, Isabelle

“…Background information. The identification of a source of stem cells able to regenerate skeletal muscle was the goal of numerous studies with the aim to…”
Get full text

Comparison of prognostic scores according to WHO classification in 170 patients with advanced mastocytosis and C‐finding treated with midostaurin by Heiblig, Maël, Gourguechon, Clément, Guilpain, Philippe, Bulai‐Livideanu, Cristina, Barete, Stéphane, Chantran, Yannick, Agopian, Julie, Brenet, Fabienne, Dubreuil, Patrice, Lespinasse, Jérémie, Lemal, Richard, Tournilhac, Olivier, Terriou, Louis, Launay, David, Bouillet, Laurence, Chatain, Catharina, Damaj, Ghandi, Ballul, Thomas, Greco, Celine, Polivka, Laura, Frenzel, Laurent, Meni, Cécile, Bouktit, Hassiba, Benabou, Dina, Gaudy‐Marqueste, Caroline, Gousseff, Marie, Le Mouel, Edwige, Neel, Antoine, Ranta, Dana, Jaussaud, Roland, Molina, Thierry Jo, Bruneau, Julie, Villarese, Patrick, Lhermitte, Ludovic, Maouche‐Chrétien, Leila, Temple, Marie, Kosmider, Olivier, Javier, Rose‐Marie, Pelletier, Fabien, Castelain, Florence, Retornaz, Frederique, Cabrera, Quentin, Zunic, Patricia, Gourin, Marie Pierre, Wierzbicka–Hainaut, Ewa, Viallard, Jean François, Lavigne, Christian, Hoarau, Cyrille, Durieu, Isabelle, Dimicoli‐Salazar, Sophie, Torregrosa‐Diaz, Jose Miguel, Wemeau, Mathieu, Soria, Angèle, Arock, Michel, Bodemer, Christine, Lortholary, Olivier, Hermine, Olivier, Rossignol, Julien

“…Advanced systemic mastocytosis (AdvSM) encompasses heterogeneous mastocytosis subtypes and is associated with poor outcomes. Although midostaurin was the first…”
Get full text

Cardiac failure in patients treated with azacitidine, a pyrimidine analogue: Case reports and disproportionality analyses in Vigibase by Perino, Justine, Mottal, Nathan, Bohbot, Yohann, Servant, Vincent, Berroneau, Aude, Poustis, Pierre, Fenaux, Pierre, Laribi, Kamel, Charbonnier, Aude, Bilion, Emilien, Calmettes, Claire, Bégaud, Bernard, Pigneux, Arnaud, Milpied, Noël, Miremont‐Salamé, Ghada, Théophile, Hélène, Dimicoli‐Salazar, Sophie

“…Aims Azacitidine (AZA), a pyrimidine analogue, is validated for high‐risk myelodysplastic syndrome or low‐blast acute myeloid leukaemia in unfit patients for…”
Get full text

Histological characterization of liver involvement in systemic mastocytosis by Rossignol, Julien, Canioni, Danielle, Aouba, Achille, Bulai‐Livideanu, Cristina, Barete, Stéphane, Lancesseur, Charles, Polivka, Laura, Madrange, Marine, Ballul, Thomas, Neuraz, Antoine, Greco, Celine, Agopian, Julie, Brenet, Fabienne, Dubreuil, Patrice, Lemal, Richard, Tournilhac, Olivier, Terriou, Louis, Launay, David, Bouillet, Laurence, Gourguechon, Clément, Frenzel, Laurent, Meni, Cécile, Gaudy‐Marqueste, Caroline, Gousseff, Marie, Le Mouel, Edwige, Hamidou, Mohamed, Neel, Antoine, Ranta, Dana, Jaussaud, Roland, Guilpain, Philippe, Molina, Thierry J, Bruneau, Julie, Lhermitte, Ludovic, Garcelon, Nicolas, Javier, Rose‐Marie, Pelletier, Fabien, Castelain, Florence, Retornaz, Frederique, Cabrera, Quentin, Zunic, Patricia, Gourin, Marie Pierre, Wierzbicka‐Hainaut, Ewa, Viallard, Jean François, Lavigne, Christian, Hoarau, Cyrille, Durieu, Isabelle, Heiblig, Maël, Dimicoli‐Salazar, Sophie, Torregrosa‐Diaz, Jose M, Soria, Angèle, Arock, Michel, Lortholary, Olivier, Bodemer, Christine, Pol, Stanislas, Mallet, Vincent, Hermine, Olivier, Damaj, Ghandi

“…Background and Aims Systemic mastocytosis (SM) is characterized by the accumulation of atypical mast cells (MCs) in organs. Liver histology of SM has been…”
Get full text

Reduced peripheral blood dendritic cell and monocyte subsets in MDS patients with systemic inflammatory or dysimmune diseases by Jachiet, Vincent, Ricard, Laure, Hirsch, Pierre, Malard, Florent, Pascal, Laurent, Beyne-Rauzy, Odile, Peterlin, Pierre, Maria, Alexandre Thibault Jacques, Vey, Norbert, D’Aveni, Maud, Gourin, Marie-Pierre, Dimicoli-Salazar, Sophie, Banos, Anne, Wickenhauser, Stefan, Terriou, Louis, De Renzis, Benoit, Durot, Eric, Natarajan-Ame, Shanti, Vekhoff, Anne, Voillat, Laurent, Park, Sophie, Vinit, Julien, Dieval, Céline, Dellal, Azeddine, Grobost, Vincent, Willems, Lise, Rossignol, Julien, Solary, Eric, Kosmider, Olivier, Dulphy, Nicolas, Zhao, Lin Pierre, Adès, Lionel, Fenaux, Pierre, Fain, Olivier, Mohty, Mohamad, Gaugler, Béatrice, Mekinian, Arsène

“…Background Systemic inflammatory and autoimmune diseases (SIADs) occur in 10–20% of patients with myelodysplastic syndrome (MDS). Recently identified VEXAS…”
Get full text

S102: LUSPATERCEPT VERSUS EPOETIN ALFA FOR TREATMENT (TX) OF ANEMIA IN ESA-NAIVE LOWER-RISK MYELODYSPLASTIC SYNDROMES (LR-MDS) PATIENTS (PTS) REQUIRING RBC TRANSFUSIONS: DATA FROM THE PHASE 3 COMMANDS STUDY by Della Porta, Matteo Giovanni, Platzbecker, Uwe, Santini, Valeria, Zeidan, Amer M., Fenaux, Pierre, Komrokji, Rami S., Shortt, Jake, Valcárcel, David, Jonášová, Anna, Dimicoli-Salazar, Sophie, Tiong, Ing Soo, Lin, Chien-Chin, LI, Jiahui, Zhang, Jennie, Carolina Giuseppi, Ana, Kreitz, Sandra, Pozharskaya, Veronika, Keeperman, Karen L., Rose, Shelonitda, Shetty, Jeevan K., Hayati, Sheida, Vodala, Sadanand, Degulys, Andrius, Paolini, Stefania, Cluzeau, Thomas, Garcia-Manero, Guillermo

Get full text

Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): interim analysis of a phase 3, open-label, randomised controlled trial by Platzbecker, Uwe, Della Porta, Matteo Giovanni, Santini, Valeria, Zeidan, Amer M, Komrokji, Rami S, Shortt, Jake, Valcarcel, David, Jonasova, Anna, Dimicoli-Salazar, Sophie, Tiong, Ing Soo, Lin, Chien-Chin, Li, Jiahui, Zhang, Jennie, Giuseppi, Ana Carolina, Kreitz, Sandra, Pozharskaya, Veronika, Keeperman, Karen L, Rose, Shelonitda, Shetty, Jeevan K, Hayati, Sheida, Vodala, Sadanand, Prebet, Thomas, Degulys, Andrius, Paolini, Stefania, Cluzeau, Thomas, Fenaux, Pierre, Garcia-Manero, Guillermo

“…Erythropoiesis-stimulating agents (ESAs) are the standard-of-care treatment for anaemia in most patients with lower-risk myelodysplastic syndromes but…”
Get full text

A Phase II prospective trial of azacitidine in steroid-dependent or refractory systemic autoimmune/inflammatory disorders and VEXAS syndrome associated with MDS and CMML by Mekinian, Arsene, Zhao, Lin Pierre, Chevret, Sylvie, Desseaux, Kristell, Pascal, Laurent, Comont, Thibaut, Maria, Alexandre, Peterlin, Pierre, Terriou, Louis, D’Aveni Piney, Maud, Gourin, Marie-Pierre, Vey, Norbert, Rauzy, Odile Beyne, Grobost, Vincent, Bezanahary, Holy, Dimicoli-Salazar, Sophie, Banos, Anne, Wickenhauser, Stefan, De Renzis, Benoit, Durot, Eric, Natarajan-Amé, Shanti, Voillat, Laurent, Chermat, Fatiha, Lemaire, Karine, Jachiet, Vincent, Himberlin, Chantal, Thépot, Sylvain, Diaz, Jose Miguel Torregrosa, Frenzel, Laurent, Gyan, Emmanuel, Denis, Guillaume, Hirsch, Pierre, Kosmider, Olivier, Ades, Lionel, Fain, Olivier, Fenaux, Pierre

Get full text

FLT3 Ligand Kinetic Profile Predicts Response to Treatment and Event-Free Survival (EFS) in Adults with High-Risk MDS/CMML Receiving CPX-351: A GFM Study by Peterlin, Pierre, Gaschet, Joëlle, Turlure, Pascal, Gourin, Marie-Pierre, Dumas, Pierre-Yves, Thepot, Sylvain, Berceanu, Ana, Park, Sophie, Hospital, Marie Anne, Cluzeau, Thomas, Torregrosa-Diaz, Jose-Miguel, Drevon, Louis, Sapena, Rosa, Chermat, Fatiha, Dimicoli-Salazar, Sophie, Jullien, Maxime, Fenaux, Pierre, Chevallier, Patrice

“…Background: Our group recently reported, in a prospective multicentre phase 2 study of 31 patients with higher-risk (HR)-MDS or CMML receiving CPX-351 as…”
Get full text

Efficacy and Safety of Luspatercept Versus Epoetin Alfa in Erythropoiesis-Stimulating Agent (ESA)-Naive Patients (Pts) with Transfusion-Dependent (TD) Lower-Risk Myelodysplastic Syndromes (LR-MDS): Full Analysis of the COMMANDS Trial by Garcia-Manero, Guillermo, Platzbecker, Uwe, Santini, Valeria, Zeidan, Amer M., Fenaux, Pierre, Komrokji, Rami S., Shortt, Jake, Valcarcel, David, Jonasova, Anna, Dimicoli-Salazar, Sophie, Tiong, Ing Soo, Lin, Chien-Chin, Li, Jiahui, Zhang, Jennie, Giuseppi, Ana Carolina, Kreitz, Sandra, Pozharskaya, Veronika, Keeperman, Karen L., Rose, Shelonitda, Prebet, Thomas, Degulys, Andrius, Paolini, Stefania, Cluzeau, Thomas, Della Porta, Matteo Giovanni

“…Introduction: ESAs are an established treatment (tx) for pts with TD LR-MDS and endogenous serum erythropoietin (sEPO) levels ≤ 500 U/L; however, eligible pts…”
Get full text

Efficacy and safety results from the COMMANDS trial: A phase 3 study evaluating luspatercept vs epoetin alfa in erythropoiesis-stimulating agent (ESA)-naive transfusion-dependent (TD) patients (pts) with lower-risk myelodysplastic syndromes (LR-MDS) by Garcia-Manero, Guillermo, Platzbecker, Uwe, Santini, Valeria, Zeidan, Amer Methqal, Fenaux, Pierre, Komrokji, Rami S., Shortt, Jake, Valcarcel, David, Jonasova, Anna, Dimicoli-Salazar, Sophie, Tiong, Ing Soo, Lin, Chien-Chin, Li, Jiahui, Kreitz, Sandra, Pozharskaya, Veronika, Shetty, Jeevan K., Degulys, Andrius, Finelli, Carlo, Cluzeau, Thomas, Della Porta, Matteo Giovanni

“…7003 Background: Most pts with LR-MDS have limited responses to ESAs, thus there is an unmet need to treat anemia and reduce TD. Here we report interim results…”
Get full text

Molecular Response Analysis By High Throughput Sequencing in Higher Risk Myelodysplastic Syndrome (HR-MDS) Treated Intensively with CPX-351 by Le Bris, Yannick, Bouzy, Simon, Ménard, Audrey, Turlure, Pascal, Chevallier, Patrice, Gourin, Marie-Pierre, Dumas, Pierre-Yves, Thepot, Sylvain, Berceanu, Anna, Park, Sophie, Hospital, Marie-Anne, Cluzeau, Thomas, Torregrosa Diaz, Jose-Miguel, Devron, Louis, Sapena, Rosa, Chermat, Fatiha, Dimicoli Salazar, Sophie, Béné, Marie C, Fenaux, Pierre, Peterlin, Pierre

Get full text

Pathophysiologic implications of elevated prevalence of hereditary alpha-tryptasemia in all mastocytosis subtypes by Polivka, Laura, Madrange, Marine, Bulai-Livideanu, Cristina, Barete, Stéphane, Ballul, Thomas, Neuraz, Antoine, Greco, Celine, Agopian, Julie, Brenet, Fabienne, Dubreuil, Patrice, Burdet, Charles, Lemal, Richard, Tournilhac, Olivier, Terriou, Louis, Launay, David, Bouillet, Laurence, Gourguechon, Clément, Damaj, Ghandi, Frenzel, Laurent, Meni, Cécile, Bouktit, Hassiba, Collange, Anne Florence, Gaudy-Marqueste, Caroline, Gousseff, Marie, Le Mouel, Edwige, Hamidou, Mohamed, Neel, Antoine, Ranta, Dana, Jaussaud, Roland, Guilpain, Philippe, Canioni, Danielle, Molina, Thierry Jo, Bruneau, Julie, Lhermitte, Ludovic, Garcelon, Nicolas, Javier, Rose-Marie, Pelletier, Fabien, Castelain, Florence, Retornaz, Frederique, Cabrera, Quentin, Zunic, Patricia, Gourin, Marie Pierre, Wierzbicka-Hainaut, Ewa, Viallard, Jean François, Lavigne, Christian, Hoarau, Cyrille, Durieu, Isabelle, Heiblig, Maël, Dimicoli-Salazar, Sophie, Torregrosa-Diaz, Jose Miguel, Soria, Angèle, Arock, Michel, Lortholary, Olivier, Bodemer, Christine, Hermine, Olivier, Rossignol, Julien

“…Mastocytosis and monoclonal mast cell (MC) activation syndrome (MMAS) are heterogeneous conditions characterized by the accumulation of atypical MCs. Despite…”
Get full text

Red Blood Cell Transfusion Burden in Myelodysplastic Syndromes (MDS) with Ring Sideroblasts (RS): A Retrospective Multicenter Study By the Groupe Francophone Des Myélodysplasies (GFM) by Jouzier, Claire, Cherait, Amina, Cony-Makhoul, Pascale, Thepot, Sylvain, Cluzeau, Thomas, Stamatoulas Bastard, Aspasia, Peterlin, Pierre, Guerci Bresler, Agnes, Dimicoli-Salazar, Sophie, Pica, Gian-Matteo, Cheze, Stephane, Santana, Clémence, Chermat, Fatiha, Fenaux, Pierre, Park, Sophie

“…Background: MDS-RS are associated with a low risk of Acute Myeloid Leukemia (AML) progression and prolonged survival in most cases, but recurring anemia whose…”
Get full text